Free Trial

Oncternal Therapeutics (ONCT) Competitors

$8.78
+0.48 (+5.78%)
(As of 06/14/2024 ET)

ONCT vs. CNTB, LFVN, ORMP, ETON, BYSI, IFRX, RLMD, PMVP, PRPH, and CLSD

Should you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include Connect Biopharma (CNTB), LifeVantage (LFVN), Oramed Pharmaceuticals (ORMP), Eton Pharmaceuticals (ETON), BeyondSpring (BYSI), InflaRx (IFRX), Relmada Therapeutics (RLMD), PMV Pharmaceuticals (PMVP), ProPhase Labs (PRPH), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical preparations" industry.

Oncternal Therapeutics vs.

Oncternal Therapeutics (NASDAQ:ONCT) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

In the previous week, Connect Biopharma had 4 more articles in the media than Oncternal Therapeutics. MarketBeat recorded 6 mentions for Connect Biopharma and 2 mentions for Oncternal Therapeutics. Oncternal Therapeutics' average media sentiment score of 0.94 beat Connect Biopharma's score of 0.58 indicating that Oncternal Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncternal Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Connect Biopharma
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Oncternal Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.36, meaning that its stock price is 136% less volatile than the S&P 500.

Connect Biopharma has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -3,160.73%. Connect Biopharma's return on equity of 0.00% beat Oncternal Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oncternal Therapeutics-3,160.73% -107.67% -91.04%
Connect Biopharma N/A N/A N/A

Oncternal Therapeutics has higher revenue and earnings than Connect Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncternal Therapeutics$790K32.90-$39.48M-$12.34-0.71
Connect BiopharmaN/AN/A-$59.50MN/AN/A

16.0% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 11.2% of Oncternal Therapeutics shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Oncternal Therapeutics presently has a consensus target price of $28.33, suggesting a potential upside of 222.70%. Connect Biopharma has a consensus target price of $6.50, suggesting a potential upside of 301.23%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Oncternal Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncternal Therapeutics
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Connect Biopharma
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Oncternal Therapeutics received 13 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 70.83% of users gave Connect Biopharma an outperform vote while only 31.25% of users gave Oncternal Therapeutics an outperform vote.

CompanyUnderperformOutperform
Oncternal TherapeuticsOutperform Votes
30
31.25%
Underperform Votes
66
68.75%
Connect BiopharmaOutperform Votes
17
70.83%
Underperform Votes
7
29.17%

Summary

Connect Biopharma beats Oncternal Therapeutics on 9 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONCT vs. The Competition

MetricOncternal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$25.99M$6.93B$5.13B$8.41B
Dividend YieldN/A2.71%2.82%4.04%
P/E Ratio-0.7114.54142.4616.38
Price / Sales32.90261.292,162.8671.82
Price / CashN/A32.8634.2631.32
Price / Book0.865.544.844.22
Net Income-$39.48M$147.28M$110.24M$216.08M
7 Day Performance4.65%0.79%-0.35%-0.47%
1 Month Performance1.86%-2.14%-1.75%-1.98%
1 Year Performance25.43%-7.43%-0.90%2.07%

Oncternal Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CNTB
Connect Biopharma
2.8034 of 5 stars
$1.77
-3.3%
$6.50
+267.2%
+63.1%$97.53MN/A0.0081Analyst Forecast
Short Interest ↓
News Coverage
Gap Up
LFVN
LifeVantage
1.398 of 5 stars
$7.47
-2.0%
N/A+39.6%$94.87M$213.40M26.68248Short Interest ↑
ORMP
Oramed Pharmaceuticals
1.345 of 5 stars
$2.33
+12.6%
N/A-42.7%$94.67M$674,000.008.9612Gap Up
High Trading Volume
ETON
Eton Pharmaceuticals
3.0196 of 5 stars
$3.63
+0.3%
$9.00
+147.9%
-5.0%$93.26M$34.30M90.7530Short Interest ↓
News Coverage
Positive News
BYSI
BeyondSpring
0 of 5 stars
$2.36
flat
N/A+104.9%$92.11M$1.75M0.0036Positive News
IFRX
InflaRx
3.0219 of 5 stars
$1.59
+1.9%
$13.50
+749.1%
-66.7%$91.86M$99,126.00-2.0462Short Interest ↓
RLMD
Relmada Therapeutics
2.7744 of 5 stars
$3.03
-0.3%
$13.50
+345.5%
+11.1%$91.42MN/A-0.9720
PMVP
PMV Pharmaceuticals
2.0875 of 5 stars
$1.77
+2.3%
$5.75
+224.9%
-70.3%$91.05MN/A-1.3363Positive News
PRPH
ProPhase Labs
1.5596 of 5 stars
$4.77
+3.0%
$11.00
+130.6%
-34.8%$91.01M$44.38M-4.42113Short Interest ↑
CLSD
Clearside Biomedical
2.5963 of 5 stars
$1.21
-3.2%
$4.50
+271.9%
-2.4%$90.43M$8.45M-2.2030Short Interest ↓

Related Companies and Tools

This page (NASDAQ:ONCT) was last updated on 6/14/2024 by MarketBeat.com Staff

From Our Partners